Data protection Impressum

Personalized Medicine

This significant financial backing underscores the potential of Alys's comprehensive pipeline targeting a broad spectrum of dermatological indications, from atopic dermatitis to psoriasis.

Alys Pharmaceuticals launches in Geneva with USD 100 million investment

19 February 2024

The breakthrough comes from the University's Autophagy Laboratory, where Prof. Patricia Boya and her team, in collaboration with the Spanish Margarita Salas Center for Biological Research (CIB-CSIC), have demonstrated the potential of specific drugs to stimulate mitophagy, thereby enhancing the ability of cells to "clean house" even as they age.

University of Fribourg discovers drug to combat age-related neuroinflammation

12 February 2024

Onward Therapeutics’ move marks a critical transition for the company into the clinical stage, solidifying its role in developing innovative cancer treatments.

Onward Therapeutics enters clinical phase with innovative cancer immunotherapy

30 January 2024

This achievement, part of the PILATUS First-In-Human Clinical study (ClinicalTrials ID: NCT06119607), marks a new era in the field of valve replacement.

Novostia successfully implants its TRIFLO Heart Valve Implant in first human patient

24 January 2024

Timeline’s new funding round, led by BOLD (Business Opportunities for L’Oréal Development), includes strategic investments from industry giants L’Oréal and Nestlé.

Timeline secures CHF 56 million to propel its pioneering role in longevity and healthy aging

24 January 2024

Nicolas Collin, Co-Founder and CEO of the Vaccine Formulation Institute (VFI), discusses the innovative approach and global impact of their work in developing high-quality, accessible adjuvants for vaccines and why Geneva was chosen as the ideal location for VFI's impactful work.

Why the Vaccine Formulation Institute chose Western Switzerland

23 January 2024

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers.

Cellestia Biotech receives CHF 2 million for its pioneering GvHD prevention therapy

23 January 2024

STALICLA has developed the first neurodevelopmental disorder-specific precision medicine platform with an initial application in autism spectrum disorder (ASD).

STALICLA secures USD 17.4 million to propel neuro precision medicine

22 January 2024

For decades, the canton of Valais has cultivated a reputation for excellence in the chemical and pharmaceutical industries, combining innovation with economic growth.

The remarkable chemical-pharmaceutical industry in the canton of Valais

This funding and partnership with the ADDF place GliaPharm at the forefront of developing effective treatments for Alzheimer’s, offering new hope in the fight against this challenging neurodegenerative disease.

GliaPharm receives USD 4.2 million to propel Alzheimer’s treatment development

20 December 2023

1 2 3 4 5 6 7 8 9 10 … 16